Oesophageal candidiasis in elderly patients: Risk factors, prevention and management

Drugs and Aging

Volumn 25, Issue 2, 2008, Pages 119-130

  Weerasuriya, Namal ^a   Snape, Jeremy ^a  

^a KING S MILL HOSPITAL   (United Kingdom)

Author keywords

Amphotericin B, therapeutic use; Candidiasis, treatment; Caspofungin, therapeutic use; Elderly; Fluconazole, therapeutic use; Flucytosine, therapeutic use; Itraconazole, therapeutic use; Micafungin, therapeutic use; Voriconazole, therapeutic use

Indexed keywords

AMPHOTERICIN B; ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; CASPOFUNGIN; CORTICOSTEROID; FLUCONAZOLE; FLUCYTOSINE; FLUTICASONE PROPIONATE; ITRACONAZOLE; MICAFUNGIN; NORFLURANE; OMEPRAZOLE; POLYENE; PROTON PUMP INHIBITOR; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANDIDA ALBICANS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DIABETES MELLITUS; ELDERLY CARE; ESOPHAGUS CANDIDIASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESTYLE; LIVER TOXICITY; NEPHROTOXICITY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENESCENCE; STOMACH PH; UNITED KINGDOM;

EID: 38949153875     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825020-00004     Document Type: Review

References (93)

1. Laine L, Boncini M. Esophageal disease in human immunodeficiency virus infections. Arch Intern Med 1994; 154: 1577-82
2. Wilcox CM, Karowe MW. Esophageal infections: aetiology, diagnosis and management. Gastroenterology 1994; 2: 188-206
3. Roseff SA, Sugar AM. Oral and esophageal candidiasis in candidiasis: pathogenesis, diagnosis and treatment. In: Bodey GP, editor. Candidiasis: pathogenesis, diagnosis and treatment. New York: Raven Press Ltd, 1993: 185-203
4. Adams F, translator. Hippocrates c460-377BC. Epidemics, book 3. Baltimore (MD): Williams & Wilkins, 1939: 23
5. Trousseau A. Lectures on clinical medicine. Vol. 2. Delivered at the Hotel-Dieu, Paris 1868 [translated by Cormack JR]. London: New Sydenham Society, 1869
6. Maibach HI, Kligman AM. The biology of experimental human cutaneous moniliasis. Arch Dermatol 1962; 85: 233-55
7. Phaosawasdi K, Rice P, Lee B, et al. Primary and secondary Candida esophagitis. Illinois Med J 1986; 169: 361-5
8. Gentles JC, La Touche CJ. Yeasts as human and animal pathogens. In: Rose AH, Harrison JS, editors. The yeasts. Vol 1. London: Academic Press, 1969: 108-82
9. Odds FC. Candida and candidosis. London: Bailliere Tindall, 1988: 94-116
10. Weerasuriya N, Snape J. A study of Candida oesophagitis in elderly patients attending a district general hospital in the UK. Dis Esophagus 2006; 19: 189-92
11. Chocarro Martinez A, Galindo Tobal F, Ruiz-Irastorza A, et al. Risk factors for esophageal candidiasis. Eur J Clin Microbiol Infect Dis 2000; 19: 96-100
12. Naito Y, Yoshikawa T, Oyamada H, et al. Esophageal candidiasis. Gastroenterology Jpn 1988; 23: 363-70
13. Bhatia V, Kochlar R, Talwar P, et al. Association of Candida with cancer of the esophagus. Indian J Gastroenterol 1989; 8: 171-2
14. Harvey CF, Mills JO, Barros AA. Oesophageal moniliasis. Br J Clin Pract 1986; 40 (1): 36-40
15. Yakoob J, Jafri W, Abid S, et al. Candidal esophagitis: risk factors in non HIV population in Pakistan. World J Gastroenterol 2003; 9: 2328-31
16. Baskol M, Ozbakir O, Gursoy S, et al. Candida esophagitis. Turk J Gastroenterol 2001; 12: 19-22
17. Scott BB, Jenkins D. Gastro-oesophageal candidiasis. Gut 1982; 23: 137-9
18. Bjorn Jensen K, Stenderup A, Brown Thomsen J, et al. Oesophageal moniliasis in malignant neoplastic disease. Acta Medica Scand 1964; 175: 455-9
19. Holt JM. Candida infection in the oesophagus. Gut 1968; 9: 227-31
20. Gundry SR, Borkon AM, McIntosh CL, et al. Candida oesophagitis following a cardiac operation and short term antibiotic prophylaxis. J Thorac Cardiovasc Surg 1980; 80: 661-8
21. Kesten S, Hyland RH, Pruzanski WR, et al. Candida oesophagitis associated with beclomethasone dipropionate aerosol therapy. Drug Intell Clin Pharm 1988; 22: 568-9
22. Kanda N, Yasuba H, Takahashi T, et al. Prevalence of esophageal candidiasis among patients treated with fluticasone propionate. Am J Gastroenterol 2003; 98: 2146-8
23. Chung CH. Oesophageal candidiasis after prolonged use of inhaled corticosteroids. Hong Kong Pract 2002; 24: 248-52
24. Simon MR, Houser WL, Smith KA, et al. Esophageal Candida as a complication of inhaled corticosteroids. Ann Allergy Asthma Immunol 1997; 79: 333-8
25. Larner AJ, Lendrum R. Oesophageal candidiasis after omeprazole therapy. Gut 1992; 33: 860-1
26. Mossiman F. Esophageal candidiasis, omeprazole treatment and organ transplantation. Transplantation 1993; 56: 492-3
27. Good A, Sharma M, Jain NP, et al. Esophageal candidiasis following omeprazole treatment: 2 cases. Indian J Gastroenterol 1995; 14: 71-2
28. Gefter WB, Laufer I, Edell S, et al. Candidiasis in obstructed esophagus. Radiology 1981; 138: 25-8
29. Troupin RH. Intramural diverticulosis and moniliasis. AMJ Roentgenol 1968; 104: 613-6
30. Castillo S, Aburashed A, Kimmelman J, et al. Diffuse intra mural esophageal pseudo diverticulosis. Gastroenterol 1972; 72: 541-2
31. deGorgolas M, Bello E, Garcia-Vazquez E, et al. In old age: AIDS review of 37 patients over 60 years old. Ann Med Intern 1999; 16: 273-6
32. Gomez MA, Hunter R, Minino A. HIV/AIDS in a late middle aged and elderly Puerto Rican population [abstract no. 127]. Abstract search tools, National HIV Prevention Conference; 1999 Aug 29-Sep 1; Atlanta (GA)
33. Parkman HP, Schwartz SS. Esophagitis and gastro duodenal disorders associated with diabetic gastro paresis. Arch Intern Med 1987; 147: 1477-80
34. Fisher BM, Lamey PJ, Samaranayake LP, et al. Carriage of Candida species in the oral cavity in diabetic patients: relationship to glycaemic control. J Oral Pathol 1987; 16: 282-4
35. Kodsi BE, Wickremesinghe PC, Kozinn PJ, et al. Candida oesophagitis, a prospective study of 27 cases. Gastroenterol 1976; 71: 715-9
36. Lehrer RI, Cline MJ. Leukocyte candidacidal activity and resistance to systemic candidiasis in patients with cancer. Cancer 1971; 27: 1211-7
37. Vazquez JA, Sobel JD. Mucosal candidiasis. Infect Dis Clin North Am 2002; 16: 793-820
38. Walsh TH, Hamilton SR, Belitos N. Esophageal candidiasis: managing our increasingly prevalent condition. Postgrad Med 1988; 84: 193-205
39. Silverman S, Luangjarmekorn L, Greenspan D. Occurrence of oral Candida in irradiated head and neck cancer patients. J Oral Med 1984; 39: 194-6
40. Odds FC. Candida and candidosis. London: Bailliere Tindall, 1988: 156-60
41. Seelig MS. The role of antibiotics in the pathogenesis of Candida infection. Am J Med 1966; 40: 887-917
42. Gencosmanoglur R, Kurtkayer-Yapicier O, Tiftikci A, et al. Mid oesophageal ulceration and Candida associated distal oesophagitis as 2 distinct clinical patterns of tetracycline or doxycycline induced oesophageal injury. J Clin Gastroenterol 2004; 38: 484-9
43. Dennis H, Itkin IG. Effectiveness and complications of aerosol dexamethasone phosphate in severe asthma. J Allergy 1964; 35: 70-3
44. Smith MJ, Hodson ME. High dose beclomethasone inhaler in the treatment of asthma. Lancet 1983; I: 265-9
45. Torak RM. Fungus infections associated with antibiotic and steroid therapy. Am J Med 1957; 22: 872-82
46. Tapper-Jones LM, Alfred MJ, Walker DM, et al. Candidal infections and populations of C. albicans in the mouths of diabetics. J Clin Pathol 1981; 24: 706-11
47. Arendorf TM, Walker DM. The prevalence and intra-oral distribution of Candida albicans in man. Arch Oral Biol 1980; 25: 1-10
48. Karmeli Y, Stalnikowitz R, Eliakim R, et al. Conventional dose omeprazole alters gastric flora. Dig Dis Sci 1995; 40: 2070-3
49. Hendel L, Svejgaard E, Walsoe I, et al. Esophageal Candida in progressive systemic sclerosis: occurrence, significance and treatment with fluconazole. Scand J Gastroenterol 1988; 23: 1182-6
50. Scaringi L, Cornacchione P, Fettucciari K, et al. Activity inhibition of cytolytic lymphocytes by omeprazole. Scand J Immunol 1996; 44: 204-14
51. Teare JP, Spedding C, Whitehead MW, et al. Omeprazole and dry mouth. Scand J Gastroenterol 1993; 30: 216-8
52. Knight L, Fletcher J. Growth of C. albicans in saliva: stimulation by glucose, associated with antibiotics, corticosteroids and diabetes mellitus. J Infect Dis 1971; 123: 371-7
53. Odds FC, Evans EGV, Taylor MAR, et al. Prevalence of pathogenic yeasts and humoral antibodies to Candida in diabetic patients. J Clin Pathol 1987; 31: 840-4
54. Wilson RM, Reeves WC. Neutrophil phagocytosis and killing in insulin dependent diabetes. Clin Exp Immunol 1986; 63: 478-84
55. Hill LVH, Tan MH, Pereira LH, et al. Association of oral candidiasis with diabetic control. J Clin Pathol 1989; 42: 502-5
56. AIDS Infonet. Older people and HIV. Factsheet no. 616. 2007 May 5. Body Health Resources Corporation [online]. Available from URL: http://www.thebody. com/content/art6036.html [Accessed 2007 Nov 1]
57. Health Promotion Agency Communicable Disease Surveillance Centre (HIV & STI department) and the Scottish Centre for Infection & Environmental Health: unpublished quarterly surveillance tables no. 75, 07/02, August 2007 [online]. Available from URL: http://www.hpa.org.uk/infections/topics_AZ/ hiv_and_sti/hiv/epidemiology/hars_tables.htm [Accessed 2007 Nov 1]
58. Martinez Hernandez PL, Valencia Ortega ME, Pena Sanchez de Rivera JM, et al. HIV infection in old age: an epidemiological and clinical study in 42 patients in Madrid. Rev Clin Esp 1997; 197: 684-9
59. Kassu A, Mekonnen A, Bekele A, et al. HIV and syphilis infection among elderly people in NW Ethiopia. Jpn J Infect Dis 2004; 57: 264-7
60. Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection: a prospective study of 110 patients. Arch Intern Med 1991; 151: 1567-72
61. Fauci AS. HIV: infectivity and mechanisms of pathogenesis. Science 1988; 239: 617-22
62. Smith PD, Ohura K, Masur H, et al. Monocyte function in AIDS. J Clin Invest 1984; 74: 2121-8
63. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89
64. Gotzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer and neutropenia. BMJ 1997; 314: 1238-44
65. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after bone marrow transplantation: a prospective randomised double blind controlled study. J Infect Dis 1995; 171: 45-52
66. Rotstein C, Bow EJ, Laverdiere M, et al. Randomised placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefits based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999; 28: 331-40
67. Shuto H, Nagata M, Terashi Y, et al. Esophageal candidiasis as a complication of inhaled steroid therapy. Jpn J Allerg 2003; 52: 1053-64
68. Kobayashi Y, Yasuba H, Kudou M, et al. Esophageal Candida as a side effect of inhaled fluticasone propionate dry powder: recovery by switching over to beclomethasone dipropionate. Int J Clin Pharm 2006; 44: 193-7
69. Stall R, Catania JA, Pollack L. Social epidemiology of AIDS and HIV infection among older Americans. In: Riley MW, Ory MC, Zablotsky D, editors. AIDS in an aging society. New York: Springer Publishing Co., 1993: 60-76
70. Catania JA, Turner H, Kegeles SM, et al. HIV transmission: risk of older heterosexuals and gays. In: Riley MW, Ory MC, Zablotsky D, editors. AIDS in an aging society. New York: Springer Publishing Co., 1993: 77-95
71. Anderson K, Gorgone R, Marlink R, et al. Transfusion acquired HIV infection among immunocompromised persons. Ann Intern Med 1986; 105: 519-27
72. Peterman TR, Stoneburner J, Allen H, et al. Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. JAMA 1988; 259: 55-8
73. Wilcox CM, Straub RF, Clark WS. Prospective evaluation of oropharyngeal findings in HIV infected patients with esophageal ulceration. Am J Gastroenterol 1995; 90: 1938-41
74. Kaplon JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons: 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002 Jun 14; 51 (RR-8): 1-52
75. Kaplan JE, Hansen D, Dworkin MS, et al. Epidemiology of HIV associated opportunistic infections in the US in the era of HAART. Clin Infect Dis 2000; 30: S5-14
76. WHO/UNAID/UNICEF. Joint news release April 2007, London
77. Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97: 339-46
78. Olmos MA, Araya V, Concetti H, et al. Oesophageal candidiasis: clinical and mycological analysis. Acta Gastroenterol Latinoam 2005; 35 (4): 211-8
79. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662-78
80. Greer ND. Voriconazole: the newest triazole antifungal agent. Proc (Bayl Univ Med Cent) 2003 Apr; 16 (2): 241-8
81. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003 Mar 1; 36 (5): 630-7
82. Maschmeyer G, Glasmacher A. Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin. Mycoses 2005; 48: 227-34
83. Wagner C, Graninger W, Presterl E, et al. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 2006; 78 (4): 161-77
84. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999; 12: 501-17
85. Vermes A, Guchelaar HA, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46: 171-9
86. Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS: a randomized trial. Ann Intern Med 1992; 117: 655-60
87. Barbaro B, Barbarini G, Calderon W, et al. Fluconazole versus itraconazole for candida esophagitis in acquired immunodeficiency syndrome. Gastroenterology 1996; 111 (5): 1169-77
88. Wilcox CM, Darouiche RO, Laine L, et al. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997; 176: 227-32
89. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004 Sep 15; 39 (6): 842-9
90. de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005 Apr 1; 21 (7): 899-907
91. Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole vs flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo-controlled study. Endoscopy 1995; 27: 377-83
92. Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole vs itraconazole- flucytosine association in the treatment of esophageal candidiasis in AIDS patients: a double-blind, multicenter placebo-controlled study: the Candida Esophagitis Multicenter Italian Study (CEMIS) Group. Chest 1996 Dec; 110 (6): 1507-14
93. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39 (1): 1-8